89Bio Inc
ETNB14.870USD
-0.090-0.60%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
2.21BMarket Cap
LossP/E TTM
More Details of 89Bio Inc Company
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.
Company Info
Ticker SymbolETNB
Company name89Bio Inc
IPO dateNov 11, 2019
CEOMr. Rohan Palekar
Number of employees93
Security typeOrdinary Share
Fiscal year-endNov 11
Address655 Montgomery Street
CitySAN FRANCISCO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94111
Phone14154329270
Websitehttps://www.89bio.com/
Ticker SymbolETNB
IPO dateNov 11, 2019
CEOMr. Rohan Palekar
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Rohan Palekar
Mr. Rohan Palekar
Chief Executive Officer, Director
Chief Executive Officer, Director
256.74K
-17.86%
Mr. Quoc Le-Nguyen
Mr. Quoc Le-Nguyen
Chief Technical Operations Officer
Chief Technical Operations Officer
95.15K
-7.47%
Mr. Francis Willard Sarena, CPA., J.D.
Mr. Francis Willard Sarena, CPA., J.D.
Chief Operating Officer
Chief Operating Officer
72.56K
-7.85%
Mr. Ryan Martins
Mr. Ryan Martins
Chief Financial Officer
Chief Financial Officer
35.99K
-17.59%
Dr. Charles A. McWherter, Ph.D.
Dr. Charles A. McWherter, Ph.D.
Independent Director
Independent Director
25.00K
+150.00%
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Independent Director
Independent Director
--
--
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
--
--
Ms. Lota S. Zoth, CPA
Ms. Lota S. Zoth, CPA
Independent Director
Independent Director
--
--
Dr. Steven M. (Steve) Altschuler, M.D.
Dr. Steven M. (Steve) Altschuler, M.D.
Independent Chairman of the Board of Director
Independent Chairman of the Board of Director
--
--
Dr. Derek Paul Di Rocco, Ph.D.
Dr. Derek Paul Di Rocco, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Rohan Palekar
Mr. Rohan Palekar
Chief Executive Officer, Director
Chief Executive Officer, Director
256.74K
-17.86%
Mr. Quoc Le-Nguyen
Mr. Quoc Le-Nguyen
Chief Technical Operations Officer
Chief Technical Operations Officer
95.15K
-7.47%
Mr. Francis Willard Sarena, CPA., J.D.
Mr. Francis Willard Sarena, CPA., J.D.
Chief Operating Officer
Chief Operating Officer
72.56K
-7.85%
Mr. Ryan Martins
Mr. Ryan Martins
Chief Financial Officer
Chief Financial Officer
35.99K
-17.59%
Dr. Charles A. McWherter, Ph.D.
Dr. Charles A. McWherter, Ph.D.
Independent Director
Independent Director
25.00K
+150.00%
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
14.02%
RA Capital Management, LP
13.41%
Suvretta Capital Management, LLC
9.58%
Deep Track Capital LP
6.41%
BlackRock Institutional Trust Company, N.A.
6.34%
Other
50.25%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
14.02%
RA Capital Management, LP
13.41%
Suvretta Capital Management, LLC
9.58%
Deep Track Capital LP
6.41%
BlackRock Institutional Trust Company, N.A.
6.34%
Other
50.25%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
39.09%
Hedge Fund
30.73%
Investment Advisor
23.07%
Venture Capital
13.70%
Research Firm
2.65%
Foundation
0.78%
Individual Investor
0.55%
Bank and Trust
0.40%
Pension Fund
0.29%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
415
160.66M
110.05%
+29.30K
2025Q1
438
159.25M
109.27%
+2.99M
2024Q4
410
127.02M
92.80%
-4.94M
2024Q3
400
110.52M
105.30%
-20.72M
2024Q2
393
109.45M
113.05%
-19.16M
2024Q1
388
104.01M
113.08%
-21.73M
2023Q4
375
99.22M
108.37%
+5.43M
2023Q3
350
77.31M
106.51%
-14.51M
2023Q2
321
82.01M
116.66%
-275.98K
2023Q1
292
75.33M
112.27%
+21.64M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
20.46M
14.02%
+371.83K
+1.85%
Mar 31, 2025
RA Capital Management, LP
19.89M
13.62%
--
--
Mar 31, 2025
Suvretta Capital Management, LLC
14.34M
9.82%
+4.13M
+40.50%
Mar 31, 2025
Deep Track Capital LP
9.32M
6.38%
+2.84M
+43.81%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.03M
6.19%
+1.98M
+28.00%
Mar 31, 2025
The Vanguard Group, Inc.
7.14M
4.89%
+1.47M
+25.85%
Mar 31, 2025
Avoro Capital Advisors LLC
6.35M
4.35%
+2.25M
+54.88%
Mar 31, 2025
State Street Global Advisors (US)
4.03M
2.76%
+1.09M
+36.84%
Mar 31, 2025
Pictet Asset Management Ltd.
4.20M
2.88%
+1.20M
+39.84%
Mar 31, 2025
Citadel Advisors LLC
5.09M
3.48%
+356.98K
+7.55%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
Fidelity Enhanced US All-Cap Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
0%
Humankind US Stock ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Fidelity Enhanced US All-Cap Equity ETF
Proportion0%
Invesco Raymond James SB-1 Equity ETF
Proportion0%
Humankind US Stock ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
